OncoMatch/Clinical Trials/NCT06718270
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Is NCT06718270 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies CAR-T cells Infusion for relapsed/refractory multiple myeloma.
Treatment: CAR-T cells Infusion — This study is a single-arm, open-label, exploratory dose-escalation and dose-finding clinical trial to evaluate the safety, efficacy, cellular pharmacokinetics and pharmacodynamics of CT0596 cells in patients with R/R MM and PCL.RRMM and RRpPCL
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
Patients with R/RMM who have received at least 3 prior lines of therapy, including at least 1 proteasome inhibitor
Must have received: immunomodulator
Patients with R/RMM who have received at least 3 prior lines of therapy, including at least 1 proteasome inhibitor and at least 1 immunomodulator (IMiD)
Must have received:
Patients with RRpPCL had received at least 1 prior line of therapy
Cannot have received: allogeneic stem cell transplant
Previous allogeneic stem cell transplantation
Cannot have received: autologous stem cell transplant
Exception: within 12 weeks prior to signing informed consent
autologous stem cell transplantation within 12 weeks prior to signing informed consent
Cannot have received:
Exception: within 14 days before informed consent
Have received treatment for the disease within 14 days before informed consent
Cannot have received: cell therapy
Exception: within 28 days before informed consent
Have received cell therapy within 28 days before informed consent
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify